Immune-Mediated Therapies in Lymphoma

被引：0
|
作者：
Forbes, Sheryl G. [1 ]
Mistry, Haleigh E. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA
来源：
SEMINARS IN ONCOLOGY NURSING | 2019年 / 35卷 / 05期
关键词：
Non-Hodgkin lymphoma; Hodgkin lymphoma; Immune-mediated therapy; Monoclonal antibody; Checkpoint inhibitors; PI3 kinase inhibitors; Immune modulators; Bruton's tyrosine kinase inhibitors; BCL-2; inhibitors; CELL TRANSPLANTATION; BRENTUXIMAB VEDOTIN; PHASE-II; HODGKIN; MANAGEMENT; NIVOLUMAB; MULTICOHORT; VENETOCLAX; FAILURE;
D O I：
10.1016/j.soncn.2019.08.004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Objective: To review types of lymphoma, risk factors, and evaluate novel immune-mediated therapies, including side effects and management of immune-mediated toxicities. Data Source: Published literature, national statistics, and Web sites. Conclusion: Novel biologic agents are being developed with the potential to improve outcomes. However, these novel agents pose unique and sometimes serious adverse events. Implications for Nursing Practice: The immune-mediated adverse events require a multidisciplinary approach and early identification. It is imperative providers and nurses are educated on the management of the unique toxicities caused by lymphoma treatment. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Immune-Mediated Therapies for Liver Cancer
    Aravalli, Rajagopal N.
    Steer, Clifford J.
    [J]. GENES, 2017, 8 (02):
  • [2] Pathogenesis and therapies of immune-mediated myopathies
    Dalakas, Marinos C.
    [J]. AUTOIMMUNITY REVIEWS, 2012, 11 (03) : 203 - 206
  • [3] Emerging biologic therapies for immune-mediated diseases
    Rosenbaum, JT
    [J]. ISOPT: PROCEEDINGS OF THE 5TH INTERNATIONAL SYMPOSIUM ON OCULAR PHARMACOLOGY AND THERAPEUTICS, 2004, : 167 - 173
  • [4] Update on immune-mediated therapies for myasthenia gravis
    Habib, Ali Aamer
    Ahmadi Jazi, Ghazaleh
    Mozaffar, Tahseen
    [J]. MUSCLE & NERVE, 2020, 62 (05) : 579 - 592
  • [5] Immune-mediated Pathogenesis and Therapies for Inflammatory Autoimmune Diseases
    Islam, Md. Asiful
    Kamal, Mohammad A.
    Zulfiker, Abu H. Md
    Gan, Siew H.
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2019, 25 (27) : 2907 - 2908
  • [6] Immune-mediated mechanisms influencing the efficacy of anticancer therapies
    Coffelt, Seth B.
    de Visser, Karin E.
    [J]. TRENDS IN IMMUNOLOGY, 2015, 36 (04) : 198 - 216
  • [7] Advances in Therapies of Cerebellar Disorders: Immune-Mediated Ataxias
    Hadjivassiliou, Marios
    [J]. CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2019, 18 (06) : 423 - 431
  • [8] Immune-mediated attack in relapsed Hodgkin's lymphoma
    Corradini, P
    Farina, L
    [J]. LANCET, 2005, 365 (9475): : 1906 - 1908
  • [9] IMMUNE-MEDIATED DISEASE AS A RISK FACTOR FOR CANINE LYMPHOMA
    KELLER, ET
    [J]. CANCER, 1992, 70 (09) : 2334 - 2337
  • [10] Safety of targeted therapies for treating immune-mediated inflammatory diseases
    Hoisnard, L.
    Zureik, M.
    Weill, A.
    Dray-Spira, R.
    Lebrun-Vignes, B.
    Meyer, A.
    Vegas, L. Pina
    Claudepierre, P.
    Mahevas, M.
    Michel, M.
    Cohen, J. L.
    Maury, S.
    El Karoui, K.
    Wolkenstein, P.
    Roy, L.
    Amiot, A.
    Grimbert, P.
    Sbidian, E.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2024, 38 : 43 - 44
12345